Back Hepatitis C

Hepatitis C

New Hepatitis C Treatments Highly Effective for HIV/HCV Coinfected People

A pair of interferon-free combinations -- AbbVie's 3-drug Viekira Pak regimen and Gilead Science's sofosbuvir/ledipasvir (Harvoni) -- demonstrated good safety and cured more than 90% of genotype 1 HIV/HCV coinfected people, according to studies published in the February 23 advance edition of the Journal of the American Medical Association.

alt

CROI 2015: Hepatitis C -- A Light at the End of the Tunnel [VIDEO]

Charles Rice from the Rockefeller University traced the development of scientific knowledge about hepatitis C virus and the evolution of its treatment in a plenary lecture at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) taking place this week in Seattle.

alt

Studies Find Risk-based Testing Misses Many People with Hepatitis C

Testing for hepatitis C virus (HCV) in primary care settings according to risk factors may fail to identify 80% of people positive for HCV antibodies, according to a report in the January 16 edition of Clinical Infectious Diseases. A related study found that a substantial number of Baby Boomers seen in an Alabama emergency department had undiagnosed chronic HCV infection.

alt

AbbVie Dual Regimen Highly Effective Against HCV Genotype 1b

A 2-drug combination consisting of AbbVie's ritonavir-boosted HCV protease inhibitor parataprevir and NS5A inhibitor ombitasvir -- part of the Viekira Pak regimen -- demonstrated a 95% cure rate for people with hepatitis C virus genotype 1b, the most common type in Japan, according to a recent company announcement.

alt

Liver Cirrhosis Is More Common in U.S. than Previously Believed

New estimates indicate that more than 600,000 people in the U.S. have liver cirrhosis -- about 200,000 more than previously thought -- according to a study published online in the Journal of Clinical Gastroenterology. Cirrhosis was associated with hepatitis C virus (HCV) infection, heavy alcohol use, and diabetes.

alt

Clinicians Report 2 Acute HCV Infections in Kaiser PrEP Program

Two HIV negative men gay receiving HIV pre-exposure prophylaxis (PrEP) through Kaiser Permanente in San Francisco were newly infected with hepatitis C virus (HCV), with sex being their only apparent risk factor, Kaiser clinicians reported in the February 18 issue of Clinical Infectious Diseases.

alt

AASLD 2014: AbbVie Next-Generation Hepatitis C Drugs Promising in Early Studies

AbbVie's investigational HCV protease inhibitor ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in patients with genotype 1 chronic hepatitis C in a 3-day monotherapy study, as well as potent and synergistic activity against multiple HCV genotypes in laboratory replicon studies, according to presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting held recently in Boston.

alt

Achillion's ACH-3102 + Sofosbuvir for 6 Weeks Shows 100% Cure Rate

Achillion's next-generation HCV NS5A inhibitor ACH-3102 plus Gilead Science's HCV polymerase inhibitor sofosbuvir (Sovaldi) taken for 6 weeks led to sustained virological response in all previously untreated genotype 1 hepatitis C patients in a small Phase 2 trial, according to a recent company announcement. Achillion now plans to test this same combination taken for just 4 weeks.

alt

AbbVie's Viekirax + Exviera "3D" Hepatitis C Regimen Approved in Europe

The European Commission last week approved AbbVie's interferon-free Viekirax plus Exviera combination regimen -- formerly known as "3D" -- for the treatment of genotype 1 chronic hepatitis C. This approval includes people with compensated liver cirrhosis, liver transplant recipients, HIV/HCV coinfected patients, and people on opioid substitution therapy for drug addiction. The commission also approved Viekirax plus ribavirin for HCV genotype 4.

alt